ALXA News 3.55 08/21/2014 04:31:54 Alexza Pharmaceuticals (A

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alexza Pharmaceuticals (ALXA) 3.55 $ALXA

Why to Buy These 5 Under-$10 Stocks ASAP
at The Street - Wed Aug 20, 5:00AM CDT
Big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release.

Alexza Pharmaceuticals Provides an Update on the Five Post-EMA Approval Studies for ADASUVE®
PR Newswire - Thu Aug 14, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its European Medicines Agency (EMA) post-approval studies for ADASUVE® inhalation powder, pre-dispensed (loxapine). As part of the ADASUVE approval process with the EMA, Alexza is required to conduct five post-approval studies:

Alexza Pharmaceuticals unveils ADASUVE in Guatemala for schizophrenia or bipolar disorder, reflecting ADASUVE 's first approval in a Latin American country
M2 - Mon Aug 11, 7:22AM CDT
Pharmaceutical company Alexza Pharmaceuticals (NasdaqGM:ALXA) on Friday announced the market availability of ADASUVE inhalation powder, pre-dispensed (loxapine) in Guatemala for treating schizophrenia or bipolar disorder, representing the first ADASUVE approval in Latin America.

Alexza Pharmaceuticals Announces the Launch of ADASUVE® (inhalation powder, loxapine) in Guatemala
PR Newswire - Fri Aug 08, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza. Ferrer is Alexza's commercial partner for ADASUVE in the EU, Latin America and Commonwealth of Independent States countries.

Downgrade Alert for Alexza Pharmaceuticals (ALXA)
Comtex SmarTrend(R) - Fri Aug 08, 7:10AM CDT
Alexza Pharmaceuticals (NASDAQ:ALXA) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $4.86 on volume of 66,000 shares, below average daily volume of 121,000. Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of proprietary products for the treatment of acute and intermittent conditions.

Alexza's net loss widens to USD6.0m in Q2 2014
M2 - Fri Aug 08, 6:43AM CDT
Pharmaceutical company Alexza Pharmaceuticals (NasdaqGM:ALXA) on Thursday disclosed a net loss of USD6.0m for the quarter ended 30 June 2014.

Alexza Reports 2014 Second Quarter Financial Results
PR Newswire - Thu Aug 07, 3:05PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended June 30, 2014. The net loss for the second quarter was $6.0 million compared to $0.8 million during the same quarter in 2013. During the three months ended June 30, 2013, Alexza recognized $42.8 million in licensing revenue associated with the signing of the Company's License and Supply Agreement with Teva Pharmaceuticals USA, Inc. The net loss for the six months ended June 30, 2014 and 2013 was $16.7 million and $21.5 million, respectively. At June 30, 2014, Alexza had consolidated cash, cash equivalents, marketable securities and restricted cash of $49.2 million.

Alexza Provides Pipeline Update
PR Newswire - Thu Jul 31, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its pipeline and new product development efforts. In the second half of 2014, Alexza expects to initiate a Phase 2a study of AZ-002 (Staccato® alprazolam), which is being developed for the management of patients with acute repetitive seizures. Additionally, Alexza has identified two new Staccato-based product candidates for development - AZ-008 and AZ-009 - which will incorporate the active pharmaceutical ingredient ropinirole, a dopamine agonist, into Alexza's proprietary Staccato system. The Company plans to develop AZ-008 for the acute treatment of restless legs syndrome (RLS) and AZ-009 for hypomobility, or freezing, during "off periods" in Parkinson's disease (PD) patients.

Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences
PR Newswire - Tue Jul 29, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is participating in two healthcare conferences during the third quarter, the 2014 Avondale Partners Healthcare 1-1 Conference and the Morgan Stanley Global Healthcare 2014 Conference. Alexza's corporate presentation will be webcast live from the Morgan Stanley Conference. The details on each event are below:

Alexza to Report 2014 Second Quarter Financial Results on Thursday, August 7, 2014
PR Newswire - Thu Jul 17, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended June 30, 2014 on Thursday, August 7, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.

Nasdaq stocks posting largest percentage increases
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:

Global Seizures Therapeutics Pipeline Review, H1 2014 - 9 Companies & 12 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ccl3gq/seizures) has announced the addition of the "Seizures - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Novartis AG - Acorda Therapeutics, Inc. - Pfizer Inc. - Upsher-Smith Laboratories, Inc. - Concert Pharmaceuticals, Inc. - Advicenne Pharma - Ultragenyx Pharmaceutical Inc. - Sage Therapeutics Drug Profiles - diazepam - midazolam hydrochloride - everolimus - diazepam - UX-007 - topiramate - alprazolam - ADV-6208 - C-10068 - CCG-63802 - Dihydroxyflavone - SAGE-NCE For more information visit http://www.researchandmarkets.com/research/ccl3gq/seizures

Alexza Announces the Promotion of Edwin S. Kamemoto, Ph.D. to Senior Vice President, Regulatory Affairs
PR Newswire - Mon Jun 30, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will have primary responsibility for leading and directing all regulatory affairs and global pharmacovigilence activities.

Alexza Pharmaceuticals closes private placement of USD45m non-recourse notes
M2 - Thu Mar 20, 7:57AM CDT
Central nervous system treatment company Alexza Pharmaceuticals (NasdaqGM:ALXA) revealed on Wednesday the completion of a private placement of USD45.0m of non-recourse notes to institutional investors.

Alexza Pharmaceuticals Announces Private Placement of $45 Million of Non-Recourse Notes
PR Newswire - Wed Mar 19, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) (Alexza) announced today that it has closed a private placement to institutional investors of $45.0 million of non-recourse notes (the "Notes" . The Notes are secured by royalties and potential milestones from U.S. sales of ADASUVE® (loxapine) inhalation powder. Alexza's commercial partner for ADASUVE in the U.S. is Teva Pharmaceuticals USA, Inc.

Alexza Pharmaceuticals and Ferrer Announce the Launch of ADASUVE® (inhalation powder, loxapine) in Romania
PR Newswire - Thu Mar 13, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Ferrer today announced that ADASUVE® inhalation powder, pre-dispensed (loxapine) is now available in Romania. Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America and the Commonwealth of Independent States countries. Ferrer is commercializing the product in Romania through a distribution agreement with Galenica, S.A.

Alexza Reports Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Thu Mar 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended December 31, 2013. The net loss for the fourth quarter was $5.7 million compared to $10.3 million during the same quarter in 2012. The net loss for the years ended December 31, 2013 and 2012 was $39.6 million and $28.0 million, respectively. At December 31, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $25.9 million.

Teva Launches ADASUVE(R) in U.S.
Business Wire - Mon Mar 03, 7:15AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today the commercial launch of ADASUVE(R) (loxapine) inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals
PR Newswire - Mon Mar 03, 7:07AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE® (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Robert A. Lippe Joins Alexza Pharmaceuticals as Executive Vice President, Operations and Chief Operations Officer
PR Newswire - Tue Feb 25, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Robert A. Lippe has joined the Company as Executive Vice President, Operations and Chief Operations Officer. In this newly created position, Mr. Lippe has responsibility for the Company's global operation functions, including strategic development and execution of clinical and commercial manufacturing, quality and compliance, supply chain and supply partner management, technology transfer, facilities, sustainment engineering and IT in support of the Company's product and technology portfolio.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 253

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 112

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
UN Integrity Accelerator Targets Corporate Corruption

Updated Category News Views 10

Corruption rarely arrives wearing a villain costume; it shows up as a rushed payment, a friendly intermediary, or a contract nobody wants examined too closely. That is why the United Nations Global Compact's new Business Integrity Accelerator deserves a sober look. Launched November 18, 2026, the programme is not a magic shield, and nobody should sell it as one. But it...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 138

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 71

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 81

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 103

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming $100 into a Remarkable Asset with ISRG

Updated Category News Views 310

Investing in Intuitive Surgical: A Decade of Growth Investing in stocks can often lead to impressive returns, and when it comes to Intuitive Surgical (NASDAQ: ISRG), this statement holds particularly true over the past decade. With a remarkable annualized return of 24.63%, Intuitive Surgical has substantially outperformed the market, making it an attractive consideration...

Continue Reading
Giftify, Inc. Empowers Consumers Amid Increasing Food Costs

Updated Category News Views 181

How Giftify, Inc. is Supporting Consumers with Savings In a time where food prices are skyrocketing, especially in the grocery sector, Giftify, Inc. (NASDAQ: GIFT), the company behind the CardCash.com platform, is stepping up to support consumers. With rising egg prices and the increasing impact of inflation, Giftify is providing a practical solution for everyday...

Continue Reading
HCA Healthcare Posts Strong Results, Showcases Growth Potential

Updated Category News Views 315

HCA Healthcare Inc. Surpasses Expectations with Q3 Results HCA Healthcare Inc. (NYSE: HCA), recognized as one of the largest hospital operators in the country, recently shared its financial results for the third quarter of 2025. The company reported a notable increase in its financial metrics, showcasing resilience and growth amidst the evolving healthcare landscape....

Continue Reading
MedEx Ambulance Addresses Security Incident Resolution Steps

Updated Category News Views 379

Understanding the Recent Data Security Incident MedEx Ambulance, known for its dedication to emergency services, has recently faced a troubling data security incident. This incident has raised concerns about unauthorized access to both patient health records and employee personal details. Although operations have continued without disruption, MedEx feels it's crucial to...

Continue Reading
Blue Apron Tops Rankings for Home Meal Delivery Services

Updated Category News Views 139

Blue Apron Achieves Top Rank for Home Meal Delivery Blue Apron has risen to the highest rank for home-cooked meals through an extensive evaluation by Expert Consumers. This independent assessment focused on various meal delivery services, gauging them based on ingredient quality, recipe clarity, sourcing transparency, ease of use, and overall support for home cooking. Why...

Continue Reading